Assessment of glycemic variability and lifestyle behaviors in healthy nondiabetic individuals according to the categories of body mass index.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
07
2023
accepted:
09
09
2023
medline:
1
11
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
There are limited data about the association between body mass index (BMI), glycemic variability (GV), and life-related factors in healthy nondiabetic adults. This cross-sectional study was carried out within our ethics committee-approved study called "Exploring the impact of nutrition advice on blood sugar and psychological status using continuous glucose monitoring (CGM) and wearable devices". Prediabetes was defined by the HbA1c level of 5.7-6.4% and /or fasting glucose level of 100-125 mg/dL. Glucose levels and daily steps were measured for 40 participants using Free Style Libre and Fitbit Inspire 2 under normal conditions for 14 days. Dietary intakes and eating behaviors were assessed using a brief-type self-administered dietary history questionnaire and a modified questionnaire from the Obesity Guidelines. All indices of GV were higher in the prediabetes group than in the healthy group, but a significant difference was observed only in mean amplitude of glycemic excursions (MAGE). In the multivariate analysis, only the presence of prediabetes showed a significant association with the risk of higher than median MAGE (Odds, 6.786; 95% CI, 1.596-28.858; P = 0.010). Additionally, the underweight (BMI < 18.5) group had significantly higher value in standard deviation (23.7 ± 3.5 vs 19.8 ± 3.7 mg/dL, P = 0.038) and coefficient variability (22.6 ± 4.6 vs 18.4 ± 3.2%, P = 0.015), compared to the normal group. This GV can be partially attributed to irregularity of eating habits. On the contrary, the overweight (BMI ≥ 25) group had the longest time above the 140 or 180 mg/dL range, which may be due to eating style and taking fewer steps (6394 ± 2337 vs 9749 ± 2408 steps, P = 0.013). Concurrent CGM with diet and activity monitoring could reduce postprandial hyperglycemia through assessment of diet and daily activity, especially in non- normal weight individuals.
Sections du résumé
BACKGROUND
There are limited data about the association between body mass index (BMI), glycemic variability (GV), and life-related factors in healthy nondiabetic adults.
METHODS
This cross-sectional study was carried out within our ethics committee-approved study called "Exploring the impact of nutrition advice on blood sugar and psychological status using continuous glucose monitoring (CGM) and wearable devices". Prediabetes was defined by the HbA1c level of 5.7-6.4% and /or fasting glucose level of 100-125 mg/dL. Glucose levels and daily steps were measured for 40 participants using Free Style Libre and Fitbit Inspire 2 under normal conditions for 14 days. Dietary intakes and eating behaviors were assessed using a brief-type self-administered dietary history questionnaire and a modified questionnaire from the Obesity Guidelines.
RESULTS
All indices of GV were higher in the prediabetes group than in the healthy group, but a significant difference was observed only in mean amplitude of glycemic excursions (MAGE). In the multivariate analysis, only the presence of prediabetes showed a significant association with the risk of higher than median MAGE (Odds, 6.786; 95% CI, 1.596-28.858; P = 0.010). Additionally, the underweight (BMI < 18.5) group had significantly higher value in standard deviation (23.7 ± 3.5 vs 19.8 ± 3.7 mg/dL, P = 0.038) and coefficient variability (22.6 ± 4.6 vs 18.4 ± 3.2%, P = 0.015), compared to the normal group. This GV can be partially attributed to irregularity of eating habits. On the contrary, the overweight (BMI ≥ 25) group had the longest time above the 140 or 180 mg/dL range, which may be due to eating style and taking fewer steps (6394 ± 2337 vs 9749 ± 2408 steps, P = 0.013).
CONCLUSIONS
Concurrent CGM with diet and activity monitoring could reduce postprandial hyperglycemia through assessment of diet and daily activity, especially in non- normal weight individuals.
Identifiants
pubmed: 37792730
doi: 10.1371/journal.pone.0291923
pii: PONE-D-23-21287
pmc: PMC10550127
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291923Informations de copyright
Copyright: © 2023 Kashiwagi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The Institutional ethics committees approving thi original study comply with the Declaration of Helsinki. The identity of the patient has been protected. The authors also declared the following potential conflicts of interest: KK, SK, and TK have been members of Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, supported by Mori Building Co., Ltd. The sponsor had no control over the interpretation, writing, or publication of this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials
Références
Nutr Metab Cardiovasc Dis. 2022 Apr;32(4):1035-1044
pubmed: 35115208
Ann Intern Med. 2002 Feb 5;136(3):201-9
pubmed: 11827496
Cardiovasc Diabetol. 2012 Sep 14;11:107
pubmed: 22973968
J Diabetes Sci Technol. 2007 Sep;1(5):695-703
pubmed: 19885137
Cardiovasc Diabetol. 2011 Dec 01;10:109
pubmed: 22132774
Diabetes Res Clin Pract. 2019 May;151:56-64
pubmed: 30935927
J Diabetes Investig. 2019 May;10(3):827-836
pubmed: 30290067
BMC Endocr Disord. 2022 Jan 11;22(1):20
pubmed: 35016646
Diabetes Care. 2017 Dec;40(12):1631-1640
pubmed: 29162583
Heart Asia. 2015 Aug 26;7(2):12-18
pubmed: 26345318
Acta Diabetol. 2018 May;55(5):479-484
pubmed: 29455425
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Clin Endocrinol Metab. 2011 Sep;96(9):2898-903
pubmed: 21778224
Sci Rep. 2019 Jun 3;9(1):8210
pubmed: 31160664
Am J Public Health. 2004 Sep;94(9):1592-5
pubmed: 15333320
Diabetes Care. 2009 Nov;32 Suppl 2:S151-6
pubmed: 19875543
Diabet Med. 2004 Apr;21(4):349-53
pubmed: 15049937
Diabetes Care. 2010 Jun;33(6):1297-9
pubmed: 20215454
Diabetol Metab Syndr. 2013 Jul 23;5:38
pubmed: 23876034
BMC Public Health. 2021 Jan 12;21(1):130
pubmed: 33435946
Lancet. 2005 Oct 1;366(9492):1197-209
pubmed: 16198769
J Diabetes Sci Technol. 2021 Sep;15(5):1198-1199
pubmed: 34024145
Diabetes Care. 1998 Oct;21(10):1619-26
pubmed: 9773720
Intern Med. 2015;54(3):303-10
pubmed: 25748739
Diabetes Care. 2008 Mar;31(3):583-4
pubmed: 18071003
PLoS One. 2015 Oct 07;10(10):e0139973
pubmed: 26445499
Diabetes Care. 2016 Jul;39(7):1175-9
pubmed: 27330126
J Diabetes Sci Technol. 2021 May;15(3):593-599
pubmed: 32064911
Am J Clin Nutr. 2013 Aug;98(2):436-43
pubmed: 23761483
Nature. 2006 Dec 14;444(7121):840-6
pubmed: 17167471
Sports Med Health Sci. 2021 Oct 11;3(4):183-193
pubmed: 35783368
Diabetes Ther. 2021 Jul;12(7):1871-1886
pubmed: 34047962
Public Health Nutr. 2011 Jul;14(7):1200-11
pubmed: 21477414
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
pubmed: 20042772
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2053-e2062
pubmed: 33512496